Dr. Rashmi Murthy, MD

• Medical Oncology

• Internal Medicine

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice, 2020-03-25

• Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial, 2023-06-21

• Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer, 2022-03-04

• Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer, 2022-07-01

• Outcomes of children exposedin uteroto chemotherapy for breast cancer, 2014-12-30

• Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab vs trastuzumab to prevent recurrences in high-risk HER2 low-expressing breast cancer patients., 2020-02-18

• Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer, 2018-11-15

• A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment, 2019-05-17

• Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer, 2018-05-23

• PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens, 2023-08-02